Pleural mesothelioma: management updates and nursing initiatives to improve patient care

References

• van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78:92–111.
   PubMed Web of Science ®Google Scholar
• Brims FJ, Maskell NA. Prognostic factors for malignant pleural mesothelioma. Curr Respir Care Rep. 2013;2:100–108.
   Google Scholar
• Moore S, Darlison, L, Tod AM. Living with mesothelioma: a literature review. Eur J Cancer Care. 2010;19:458–468.
   Web of Science ®Google Scholar
• Moore S, Darlison L. Improving the nursing care of patients with mesothelioma. Nurs Stand. 2011;25:35–38.
   Google Scholar
• Thompson JK, Westbom CM, Shukla A. Malignant mesothelioma: development to therapy. J Cell Biochem. 2014;115:1–7.
   PubMed Web of Science ®Google Scholar
• Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Ther. 2013;20:150–156.
   PubMed Web of Science ®Google Scholar
• Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011;32:102–110.
   PubMed Web of Science ®Google Scholar
• Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013;110:319–326.
   PubMed Web of Science ®Google Scholar
• Okello C, Treasure T, Nicholson AG, Peto J, Møller H. Certified causes of death in patients with mesothelioma in South East England. BMC Cancer. 2009;9:28.
   PubMed Web of Science ®Google Scholar
• Chen SE, Pace MB. Malignant pleural mesothelioma. Am J Health Syst Pharm. 2012;69:377–385.
   Web of Science ®Google Scholar
• Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths and hypotheses. J Cell Physiol. 2012;227:44–58.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–2090.
   Web of Science ®Google Scholar
• Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:97–104.
   PubMedGoogle Scholar
• Greillier L, Astoul P. Mesothelioma and asbestos-related pleural diseases. Respiration. 2008;76:1–15.
   PubMed Web of Science ®Google Scholar
• Hasegawa S. Early mesothelioma revisited. Int J Clin Oncol. 2012;17:30–32.
   Web of Science ®Google Scholar
• Mott FE. Mesothelioma: a review. Ochsner J. 2012;12:70–79.
   PubMedGoogle Scholar
• Steer J, Bough G, Razak AR, Meachery GJ, Hughes A. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience. Clin Oncol (R Coll Radiol). 2010;22:231–235.
   Web of Science ®Google Scholar
• Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer. 2006;14:11–21.
   PubMed Web of Science ®Google Scholar
• Goudar RK. Management options for malignant pleural mesothelioma: clinical and cost considerations. Drugs. 2007;67:1149–1165.
   Web of Science ®Google Scholar
• Nowak AK, Bydder S. Management of malignant pleural mesothelioma. Asia PacJ Clin Oncol. 2007;3:177–186.
   Web of Science ®Google Scholar
• Ambrogi V, Mineo D, Gatti A, Pompeo E, Mineo TC. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol. 2009;100:199–204.
   PubMed Web of Science ®Google Scholar
• Lee CW, Martin J, MacRae R, et al. Malignant mesothelioma: Canadian perspective and research directions. Curr Oncol. 2008;15:104–111.
   Web of Science ®Google Scholar
• Lee SF, O’Connor MM, Chapman Y, Hamilton V, Francis K. A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. Rural Remote Health. 2009;9:1183.
   Google Scholar
• Flores RM, Riedel E, Donington JS, et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5:1649–1654.
   PubMed Web of Science ®Google Scholar
• Greillier L, Bass P, Welch JJ, Hasan B, Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375–390.
   PubMed Web of Science ®Google Scholar
• Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:121–124.
   PubMedGoogle Scholar
• Baas P. Optimising survival in malignant mesothelioma. Lung Cancer. 2007;57 Suppl 2:S24–S29.
   Google Scholar
• Bueno R. Making the case for molecular staging of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:188–193.
   Google Scholar
• Waite K, Gilligan D. The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol). 2007;19:182–187.
   Web of Science ®Google Scholar
• Fuhrer G, Lazarus AA. Mesothelioma. Dis Mon. 2011;57:40–54.
   Web of Science ®Google Scholar
• Jenkins P, Milliner R, Salmon C. Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma. Eur J Cancer. 2011;47:2143–2149.
   Web of Science ®Google Scholar
• Mollberg NM, Vigneswaran Y, Kindler HL, et al. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012;94:1086–1093.
   Web of Science ®Google Scholar
• Suzuki H, Asami K, Hirashima T, et al. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis. Lung. 2014;192:191–195.
   PubMed Web of Science ®Google Scholar
• Palmer C, Thain C. Strategies to ensure effective and empathetic delivery of bad news. Cancer Nurs Pract. 2010;9:24–27.
   Google Scholar
• Bölükbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011;71:75–81.
   PubMed Web of Science ®Google Scholar
• Su S. Mesothelioma: path to multimodality treatment. Semin Thorac Cardiovasc Surg. 2009;21:125–131.
   Google Scholar
• Jackman DM. Current options for systemic therapy in mesothelioma. Semin Respir Crit Care Med. 2009;21:154–158.
   Google Scholar
• Ribi K, Bernhard J, Schuller JC, et al. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer. 2008;61:398–404.
   Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Borghaei H, et al. Malignant pleural mesothelioma. J Natl Cancer Compr Canc Netw. 2012;10:26–41.
   PubMed Web of Science ®Google Scholar
• van Thiel E, Gaafar R, van Meerbeeck JP. European guidelines for the management of malignant pleural mesothelioma. J Advanc Res. 2011;2:281–288.
   Google Scholar
• Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:201–216.
   PubMed Web of Science ®Google Scholar
• Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy. Semin Thorac Cardiovasc Surg. 2009;21:132–148.
   PubMedGoogle Scholar
• Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer. 2012;77:151–155.
   PubMed Web of Science ®Google Scholar
• Ploenes T, Osei-Agyemang T, Krohn A, et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann. 2012;21:48–55.
   Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–772.
   PubMed Web of Science ®Google Scholar
• Sharif S, Zahid I, Routledge T, Scarci M. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12:1040–1045.
   Web of Science ®Google Scholar
• Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis. 2008;3:34.
   PubMed Web of Science ®Google Scholar
• Lee C, Bayman N, Swindell R, Faivre-Finn C. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer. 2009;66:150–156.
   PubMed Web of Science ®Google Scholar
• Froment M, Frechette E, Dagnautl A. Prophylactic irradiation of intervention sites in malignant pleural mesothelioma. Radiother Oncol. 2011;101:307–310.
   Web of Science ®Google Scholar
• Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:159–163.
   PubMedGoogle Scholar
• Quispel-Janssen JM, Baas P. Emerging therapies for malignant pleural mesothelioma. Curr Respir Care Rep. 2012;1:91–100.
   Google Scholar
• Garland LL. Chemotherapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:181–188.
   Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010;36:24–32.
   PubMed Web of Science ®Google Scholar
• Metintas M, Ak G, Erginel S, et al. A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005: a single institution experience. Lung Cancer. 2007;55:379–387.
   PubMed Web of Science ®Google Scholar
• Stahel RA. Malignant pleural mesothelioma: a new standard of care. Lung Cancer. 2006;54 Suppl 2:S9–S14.
   Google Scholar
• Kao SC, van Zandwijk N, Corte P, Clarke C, Clarke S, Vardy J. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Support Care Cancer. 2013;21:1879–1884.
   Web of Science ®Google Scholar
• Weder W, Opitz I, Stahel R. Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:172–176.
   Google Scholar
• Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:149–153.
   PubMedGoogle Scholar
• Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:163–172.
   Web of Science ®Google Scholar
• Stahel RA, Felley-Bosco E, Optiz I, Weder W. Malignant pleural mesothelioma. Future Oncol. 2009;5:391–402.
   Web of Science ®Google Scholar
• Tonoli S, Vitali P, Scotti V, et al. Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother Oncol. 2011;101:311–315.
   PubMed Web of Science ®Google Scholar
• Surmont VF, van Thiel ER, Vermaelen K, van Meerbeeck JP. Investigational approaches for mesothelioma. Front Oncol. 2011;1:1–15.
   Google Scholar
• Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013;182:1065–1077.
   PubMed Web of Science ®Google Scholar
• Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 2006;239:183–189.
   PubMed Web of Science ®Google Scholar
• Ali G, Boldrini L, Lucchi M, et al. Treatment with interleukin-2 in malignant pleural mesotheliomaimmunological and angiogenetic assessment and prognostic impact. Br J Cancer. 2009;101:1869–1875.
   Web of Science ®Google Scholar
• Buikhusien WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013;14:543–551.
   Web of Science ®Google Scholar
• Friedberg JS. Photodynamic therapy for malignant pleural mesothelioma: the future of treatment? Expert Rev Respir Med. 2011;5:49–63.
   Web of Science ®Google Scholar
• Vachani A, Moon E, Albelda SM. Gene therapy for mesothelioma. Curr Treat Options Oncol. 2011;12:173–180.
   PubMed Web of Science ®Google Scholar
• Abrahm JL. Palliative care for the patient with mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:164–171.
   PubMedGoogle Scholar
• Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371:1685–1694.
   PubMed Web of Science ®Google Scholar
• Kao SC, Vardy J, Harvie R, et al. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Cancer Care. 2013;21:697–705.
   PubMed Web of Science ®Google Scholar
• Arber A, Spencer L. ‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology. 2013;22:1528–1533.
   PubMed Web of Science ®Google Scholar
• Moore S, Teehan C, Cornwall A, Ball K, Thomas J. ‘Hands of Time’: the experience of establishing a support group for people affected by mesothelioma. Eur J Cancer Care. 2008;17:585–592.
   Web of Science ®Google Scholar
• Dooley JJ, Wilson JP, Anderson VA. Stress and depression of facing death: investigation of psychological symptoms in patients with mesothelioma. Aust J Psychol. 2010;62:160–168.
   Web of Science ®Google Scholar
• Granieri A, Tamburello S, Tamburello A, et al. Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers. Neuropsychiatr Dis Treat. 2013;9:1193–1202.
   PubMed Web of Science ®Google Scholar
• Hughes N, Arbor A. The lived experience of patients with pleural mesothelioma. Int J Palliat Nurs. 2008;14:66–71.
   PubMedGoogle Scholar
• Thomas S, Bausewein C, Higginson I, Booth S. Breathlessness in cancer patients: implications, management and challenges. Eur J Oncol Nurs. 2011;15:459–469.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Tan SK, Read CA, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013;68:594–596.
   PubMed Web of Science ®Google Scholar
• Salminen EK, Silvoniemi M, Syrjänen K, Kaasa S, Kloke M, Klepstad P. Opioids in pain management of mesothelioma and lung cancer patients. Acta Oncol. 2013;52:30–37.
   PubMed Web of Science ®Google Scholar
• Robotin M, Holliday C, Bensoussan A. Defining research priorities in complementary medicine in oncology. Complement Ther Med. 2012;20:345–352.
   Web of Science ®Google Scholar
• Morris GS, Gallagher GH, Baxter MF, et al. Pulmonary rehabilitation improves functional status in oncology patients. Arch Phys Med Rehabil. 2009;90:837–841.
   PubMed Web of Science ®Google Scholar
• Bakitas M, Bishop MF, Caron P, Stephens L. Developing successful models of cancer palliative care services. Semin Oncol Nurs. 2010;26:266–284.
   Google Scholar